Aptalis Pharma, NovaMedica deal

Aptalis granted NovaMedica exclusive rights to develop and commercialize three of Aptalis' gastrointestinal products - Pylera, Lacteol and Panzytrat - in Russia. NovaMedica will complete requirements to obtain regulatory approval in Russia. NovaMedica expects to launch the products in the country in 2014-15. NovaMedica said financial terms have not been disclosed, and Aptalis could not be reached. ...